Geode Capital Management’s LAVA Therapeutics LVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-14,170
| Closed | -$22.1K | – | 4524 |
|
|
2025
Q3 | $22.1K | Hold |
14,170
| – | – | ﹤0.01% | 4408 |
|
|
2025
Q2 | $18.7K | Sell |
14,170
-1,994
| -12% | -$2.54K | ﹤0.01% | 4368 |
|
|
2025
Q1 | $20.5K | Hold |
16,164
| – | – | ﹤0.01% | 4340 |
|
|
2024
Q4 | $15.4K | Buy |
16,164
+5,040
| +45% | +$7.91K | ﹤0.01% | 4406 |
|
|
2024
Q3 | $18.5K | Hold |
11,124
| – | – | ﹤0.01% | 4402 |
|
|
2024
Q2 | $20K | Hold |
11,124
| – | – | ﹤0.01% | 4450 |
|
|
2024
Q1 | $37K | Hold |
11,124
| – | – | ﹤0.01% | 4377 |
|
|
2023
Q4 | $17.6K | Hold |
11,124
| – | – | ﹤0.01% | 4534 |
|
|
2023
Q3 | $16.6K | Hold |
11,124
| – | – | ﹤0.01% | 4657 |
|
|
2023
Q2 | $22.6K | Hold |
11,124
| – | – | ﹤0.01% | 4646 |
|
|
2023
Q1 | $18.5K | Hold |
11,124
| – | – | ﹤0.01% | 4712 |
|
|
2022
Q4 | $38K | Hold |
11,124
| – | – | ﹤0.01% | 4665 |
|
|
2022
Q3 | $50K | Hold |
11,124
| – | – | ﹤0.01% | 4764 |
|
|
2022
Q2 | $31K | Hold |
11,124
| – | – | ﹤0.01% | 4863 |
|
|
2022
Q1 | $48K | Buy |
11,124
+1,038
| +10% | +$5.27K | ﹤0.01% | 4813 |
|
|
2021
Q4 | $55K | Hold |
10,086
| – | – | ﹤0.01% | 4842 |
|
|
2021
Q3 | $59K | Sell |
10,086
-2,911
| -22% | -$20.9K | ﹤0.01% | 4761 |
|
|
2021
Q2 | $141K | Buy |
+12,997
| New | +$161K | ﹤0.01% | 4465 |
|
Geode Capital Management's LVTX Position: Q4 2025 in Review
Geode Capital Management sold out of LAVA Therapeutics (LVTX) in Q4 2025, closing a stake of 14,170 shares — an estimated $22.1K sold.
Geode Capital Management first reported a position in LVTX in Q2 2021 and held it in 18 quarters. The position peaked at $141K in Q2 2021. 0 funds tracked by Wall St. Rank hold LVTX as of Q4 2025.
- Geode Capital Management reported no remaining LAVA Therapeutics position as of Q4 2025 after selling out during the quarter.
- Geode Capital Management sold 14,170 LAVA Therapeutics shares in Q4 2025, an estimated $22.1K.
- Geode Capital Management first reported a position in LAVA Therapeutics in Q2 2021 and held it in 18 quarters.
- Geode Capital Management's LAVA Therapeutics position peaked at $141K in Q2 2021.
- 0 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2025.
Based on Geode Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.